The substantial outperformance of Cytokinetics compared to the market, as evidenced by its 61.18% annualized return over the past 5 years, suggests a strong positive momentum for the company. This performance, coupled with a significant market capitalization of $7.93 billion, indicates robust investor confidence and potential for continued growth, likely leading to a positive short-term impact on CYTK's stock price.